Metsera stock decline as Novo withdraws from Pfizer bidding
The Metsera stock decline reflects investor concerns following Novo Nordisk's withdrawal from the bidding process, impacting the company's valuation and market
Pfizer obesity drug bid Boosted After US Regulator Warns
Pfizer obesity drug bid concluded with Pfizer securing approval after competitive bidding and regulatory influences, marking a significant move in the obesity
Novo Nordisk Metsera Takeover: Mike Doustdar Eyes Future
Despite losing out in the Novo Nordisk Metsera takeover, the company remains committed to pursuing strategic acquisitions to strengthen its position in the
Pfizer Novo Nordisk Rivalry Escalates as Novo Nordisk Calls
The Pfizer Novo Nordisk rivalry highlights the intense competition among leading pharmaceutical companies for assets in the growing obesity drug sector,